NRXP · CIK 0001719406
NRX Pharmaceuticals, Inc.
Annual figures as reported, FY2017–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$1.2M
Net income
−$28.6M
▼ −13.9% vs FY2024
Free cash flow
−$10.6M
▲ +50.9% vs FY2023
Diluted EPS
−$1.34
▲ +43.2% vs FY2024
Revenue
Annual, as reported
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersRevenue — Mar ’26 quarter
$1.1M
Net income — Mar ’26 quarter
−$1.4M
▲ +74.1% vs Mar ’25
Diluted EPS — trailing 12 months
−$1.04
▲ +46.9% vs Mar ’25
Quarterly revenue
Discrete quarters; Q4 derived from the annual figure
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Mar ’26 | $1.1M | — | — | −$1.4M | −133.9% | −$0.04 |
| Sep ’25 | $242K | — | — | −$5.9M | −2433.9% | −$0.27 |
| Mar ’25 | $0 | — | — | −$5.5M | — | −$0.34 |
| Sep ’24 | $0 | — | — | −$1.6M | — | −$0.15 |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationDiluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedShare count change (split-adjusted)
+524.5%
5y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|---|---|---|
| FY2025 | 58.8% | −1324.4% | −2336.5% | — | −220.9% | 0.31× | — |
| FY2024 | — | — | — | — | −688.2% | 0.15× | — |
| FY2023 | — | — | — | — | −412.2% | 0.36× | — |
| FY2022 | — | — | — | −536.6% | −154.0% | 1.66× | 1.42× |
| FY2021 | — | — | — | −447.3% | −284.3% | 2.74× | — |
| FY2020 | — | — | — | — | −1760.5% | 0.06× | — |
| FY2019 | — | — | — | — | 1.3% | 0.11× | — |
| FY2018 | — | — | — | 1.3% | 0.1% | 0.05× | — |
| FY2017 | — | — | — | — | — | 5.76× | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $1.2M | $720K | −$16.2M | −$28.6M | −$1.34 | −$14.1M | — | $13.0M | $28.9M | −$15.9M | $7.8M | — |
| FY2024 | $0 | $0 | −$18.5M | −$25.1M | −$2.36 | −$10.6M | $0 | $3.7M | $26.9M | −$23.2M | $1.4M | — |
| FY2023 | $0 | — | −$27.8M | −$30.1M | −$3.98 | −$21.7M | $3K | $7.3M | $19.0M | −$11.7M | $4.6M | $9.2M |
| FY2022 | — | — | −$44.3M | −$39.8M | −$6.00 | −$39.8M | $10K | $25.8M | $18.4M | $7.4M | $20.1M | $10.5M |
| FY2021 | — | — | −$115.8M | −$93.1M | −$19.80 | −$37.7M | $7K | $32.7M | $11.9M | $20.8M | $27.6M | — |
| FY2020 | — | — | −$51.4M | −$51.8M | −$15.10 | −$2.3M | $2K | $2.9M | $46.7M | −$43.8M | $1.9M | — |
| FY2019 | — | — | −$713K | $408K | −$1.10 | −$793K | — | $32.1M | $2.6M | −$4.8M | $877K | — |
| FY2018 | — | — | −$1.0M | $66K | −$2.90 | −$473K | — | $70.8M | $1.3M | $5.0M | — | — |
| FY2017 | — | — | — | — | — | — | — | $69.6M | $93K | $0 | — | — |
Latest filings
the most recent regulatory filings8-KCurrent report — material event2026-06-04 ↗424B5Prospectus2026-06-03 ↗8-KCurrent report — material event2026-06-02 ↗424B5Prospectus2026-06-02 ↗25-NSEDelisting notice2026-05-22 ↗10-QQuarterly report2026-05-15 ↗SCHEDULE 13G/ASEC filing2026-05-15 ↗8-KCurrent report — material event2026-03-24 ↗10-KAnnual report2026-03-23 ↗DEFA14AProxy statement2026-02-24 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.